Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-ITNK Cells Targeting CD70 and CLL1 for R/R AML
NCT07336875Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of CAR70C1-ITNK in acute myeloid leukemia (AML), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate at 3 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
CAR70C1-ITNK
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07336875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336875.